摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethan-1-one | 638214-65-0

中文名称
——
中文别名
——
英文名称
1-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethan-1-one
英文别名
1-[2-(methyloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone;1-(2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanone;1-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone
1-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethan-1-one化学式
CAS
638214-65-0
化学式
C15H21BO4
mdl
——
分子量
276.14
InChiKey
AMWRGILUMRPTIL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: Design, synthesis and biological evaluation
    摘要:
    A series of novel biphenyl urea derivates were synthesized and investigated for their potential to inhibit vascular endothelial growth factor receptor-2 (VEGFR-2). In particular, A7, B3 and B4 displayed significant enzymatic inhibitory activities, with IC50 values of 4.06, 4.55 and 5.26 nM. Compound A7 exhibited potent antiproliferative activity on several cell lines. SAR study suggested that the introduction of methyl at ortho-position of the biphenyl urea and tertiary amine moiety could improve VEGFR-2 inhibitory activity and antitumor effects. Molecular docking indicated that the urea moiety formed four hydrogen bonds with DFG residue. These biphenyl ureas could serve as promising lead compounds for further optimization. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2013.11.027
  • 作为产物:
    参考文献:
    名称:
    Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors
    摘要:
    VEGFR-2 在血管生成过程中起着关键作用,VEGFR-2 抑制剂已被广泛用于治疗癌症。我们一直在努力寻找强效的新型 VEGFR-2 抑制剂作为抗肿瘤药物,在此过程中,我们发现了一种具有联苯支架的强效先导化合物(HMQ-16)。将 HMQ-16 中的芳基氨基甲酰基重新排列并替换为脲基,产生了一系列新型 VEGFR-2 抑制剂。为了增强与 VEGFR-2 的亲和力,4′-乙酰基被转化为肟基。研究人员设计并合成了 14 种联苯脲衍生物,作为有效的 VEGFR-2 抑制剂。其中六种(T2、T5、T7、T9、T11、T14)表现出与索拉非尼相当的强效 VEGFR-2 抑制活性。化合物 T7 的 IC50 值为 1.08 nM,效力最强。酶和细胞检测结果表明,T7 有可能成为一种有价值的先导化合物,有待进一步优化。
    DOI:
    10.1039/c3md00192j
点击查看最新优质反应信息

文献信息

  • [EN] PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS<br/>[FR] ACIDE PHENYLALKANOIQUE ET DERIVES D'ACIDE PHENYLOXYALKANOIQUE EN TANT QU'ACTIVATEURS DE HPPAR
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2004000315A1
    公开(公告)日:2003-12-31
    The present invention provides a compound of formula (I):wherein:R1 and R2 are independently H or C1-3 alkyl;X represents a O or (CH2)n where n is 0, 1 or 2;R3and R4 independently represent H, C1-3 alkyl, -OCH3, -CF3, allyl, or halogen;X1 represents O, S, SO2, SO, or CH2;R5 and R6 independently represent hydrogen, C1-6 alkyl (including branched alkyl and optionally substituted by one or more halogens or C1-6alkoxy), or together with the carbon atom to which they are bonded form a 3-6 membered cycloalkyl ring;R7 represents a phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 nitrogen atoms wherein the phenyl or heteroaryl group is substituted by 1, 2 or 3 moieties selected from the group consisting of halogen, C1-6 alkoxy, C1-6 alkyl, CF3, hydroxy, or phenyl (which may be optionally substituted by one or more C1-3 alkyl, -OC1-3 alkyl, CN, acetyl, hydroxy, halogen or CF3).
    本发明提供了一种具有以下结构的化合物(I):其中:R1和R2分别独立地表示H或C1-3烷基;X代表O或(CH2)n,其中n为0、1或2;R3和R4独立地表示H、C1-3烷基、-OCH3、-CF3、烯丙基或卤素;X1代表O、S、SO2、SO或 ;R5和R6独立地表示氢、C1-6烷基(包括支链烷基,并且可以选择性地被一个或多个卤素或C1-6烷氧基取代),或者与它们键合的碳原子一起形成一个3-6环状烷基环;R7表示苯基或含有1、2或3个氮原子的6元杂芳基,其中苯基或杂芳基被选自卤素、C1-6烷氧基、C1-6烷基、 、羟基或苯基(可以选择性地被一个或多个C1-3烷基、-OC1-3烷基、CN、乙酰基、羟基、卤素或 取代)的1、2或3个取代基取代。
  • Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
    申请人:Bell Richard
    公开号:US20060089394A1
    公开(公告)日:2006-04-27
    A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:
    化合物的公式(I)或其药学上可接受的盐、溶剂化合物或可解酯,其中:
  • Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators
    申请人:SmithKline Beecham Corporation
    公开号:US07338960B2
    公开(公告)日:2008-03-04
    A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:
    化合物公式(I)或其药学上可接受的盐、溶剂化物或可解酯,其中:
  • Sequential Ir/Cu-Mediated Method for the <i>Meta</i>-Selective C–H Radiofluorination of (Hetero)Arenes
    作者:Jay S. Wright、Liam S. Sharninghausen、Sean Preshlock、Allen F. Brooks、Melanie S. Sanford、Peter J. H. Scott
    DOI:10.1021/jacs.1c00523
    日期:2021.5.12
查看更多